FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089661281> ?p ?o ?g. }

• W3089661281 endingPage "A17" @default.
• W3089661281 startingPage "A17" @default.
• W3089661281 abstract "Abstract Melanoma accounts for about 1% of skin cancers but causes the majority of skin cancer-related deaths. Despite progress in treating melanoma with immunotherapy and targeted therapy, melanoma patients still suffer from relapse due to resistance to these treatments. A better understanding of the molecular mechanisms that contribute to melanomagenesis and resistance may provide novel avenues for the development of improved treatment strategies. To accelerate the speed, increase the throughput, and lower the cost of delineating such mechanisms in vivo, we developed a novel embryonic stem cell-genetically engineered mouse-modeling (ESC-GEMM) platform. We generated ESC lines harboring twelve combinations of four common driver mutations (BRAF-V600E, NRAS-Q61R, loss of PTEN, loss of CDKN2A) that can be efficiently targeted by recombination-mediated cassette exchange (RMCE) to introduce inducible alleles of interest. Importantly, all of our ESC lines are capable of producing high-contribution chimeras, which exhibit the same melanoma kinetics and overall survival as conventionally bred mice. Thus, our platform offers readily adaptable melanoma models whose melanoma phenotypes range from long latency/low penetrance to aggressive melanoma with complete penetrance. We employed our ESC-GEMM approach to compare the efficiency of gene depletion by conditional knockout, CRISPR/Cas9, or RNAi. We found that CRISPR/Cas9 depletion of Pten on a Braf-V600E background produces fewer melanomas but with nearly the same latency as conditional knockout using the Cre-lox system. Silencing of Pten with inducible shRNA resulted in significantly increased latency as well as in melanomas with a distinct macroscopic appearance and widespread lymph node metastases. While inducible shRNAs allowed us to restore Pten expression in established melanomas, depletion of Pten with inducible CRISPR enabled us to control the number of moles/melanomas by limiting the duration of Cas9 expression. We also used inducible CRISPR to sequentially activate Braf-V600E and delete Pten, which more closely mimics the sequence of events in human melanomas. Interestingly, while sequential introduction of these genetic changes had no effect on the overall survival, a subset of mice developed a significantly greater number of tumors. Finally, we established melanoma cell lines from untargeted chimeras, which can be targeted with Tet-inducible expression cassettes and transplanted into syngeneic hosts. Taken together, we have established a speedy mouse-modeling platform that will stimulate and accelerate in vivo melanoma research, provide a powerful resource to investigate the pathobiology of melanomagenesis, and allow the genetic and pharmacologic evaluation of novel treatments. Citation Format: Ilah Bok, Jordan Reff, Arianna Nenci, Jose G. Gonzalez, Florian A. Karreth. A versatile mouse-modeling platform for rapid in vivo melanoma studies [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr A17." @default.
• W3089661281 created "2020-10-08" @default.
• W3089661281 creator A5017354889 @default.
• W3089661281 creator A5035941384 @default.
• W3089661281 creator A5048984312 @default.
• W3089661281 creator A5051199851 @default.
• W3089661281 creator A5081527747 @default.
• W3089661281 date "2020-10-01" @default.
• W3089661281 modified "2023-09-23" @default.
• W3089661281 title "Abstract A17: A versatile mouse-modeling platform for rapid in vivo melanoma studies" @default.
• W3089661281 doi "https://doi.org/10.1158/1538-7445.mel2019-a17" @default.
• W3089661281 hasPublicationYear "2020" @default.
• W3089661281 type Work @default.
• W3089661281 sameAs 3089661281 @default.
• W3089661281 citedByCount "0" @default.
• W3089661281 crossrefType "journal-article" @default.
• W3089661281 hasAuthorship W3089661281A5017354889 @default.
• W3089661281 hasAuthorship W3089661281A5035941384 @default.
• W3089661281 hasAuthorship W3089661281A5048984312 @default.
• W3089661281 hasAuthorship W3089661281A5051199851 @default.
• W3089661281 hasAuthorship W3089661281A5081527747 @default.
• W3089661281 hasConcept C104317684 @default.
• W3089661281 hasConcept C119056186 @default.
• W3089661281 hasConcept C121608353 @default.
• W3089661281 hasConcept C127716648 @default.
• W3089661281 hasConcept C164659718 @default.
• W3089661281 hasConcept C190283241 @default.
• W3089661281 hasConcept C21790070 @default.
• W3089661281 hasConcept C2777609662 @default.
• W3089661281 hasConcept C2777658100 @default.
• W3089661281 hasConcept C2780265364 @default.
• W3089661281 hasConcept C2781187634 @default.
• W3089661281 hasConcept C502942594 @default.
• W3089661281 hasConcept C526805850 @default.
• W3089661281 hasConcept C54355233 @default.
• W3089661281 hasConcept C71924100 @default.
• W3089661281 hasConcept C86554907 @default.
• W3089661281 hasConcept C86803240 @default.
• W3089661281 hasConcept C98108389 @default.
• W3089661281 hasConceptScore W3089661281C104317684 @default.
• W3089661281 hasConceptScore W3089661281C119056186 @default.
• W3089661281 hasConceptScore W3089661281C121608353 @default.
• W3089661281 hasConceptScore W3089661281C127716648 @default.
• W3089661281 hasConceptScore W3089661281C164659718 @default.
• W3089661281 hasConceptScore W3089661281C190283241 @default.
• W3089661281 hasConceptScore W3089661281C21790070 @default.
• W3089661281 hasConceptScore W3089661281C2777609662 @default.
• W3089661281 hasConceptScore W3089661281C2777658100 @default.
• W3089661281 hasConceptScore W3089661281C2780265364 @default.
• W3089661281 hasConceptScore W3089661281C2781187634 @default.
• W3089661281 hasConceptScore W3089661281C502942594 @default.
• W3089661281 hasConceptScore W3089661281C526805850 @default.
• W3089661281 hasConceptScore W3089661281C54355233 @default.
• W3089661281 hasConceptScore W3089661281C71924100 @default.
• W3089661281 hasConceptScore W3089661281C86554907 @default.
• W3089661281 hasConceptScore W3089661281C86803240 @default.
• W3089661281 hasConceptScore W3089661281C98108389 @default.
• W3089661281 hasIssue "19_Supplement" @default.
• W3089661281 hasLocation W30896612811 @default.
• W3089661281 hasOpenAccess W3089661281 @default.
• W3089661281 hasPrimaryLocation W30896612811 @default.
• W3089661281 hasRelatedWork W1788793669 @default.
• W3089661281 hasRelatedWork W2028752124 @default.
• W3089661281 hasRelatedWork W2039627657 @default.
• W3089661281 hasRelatedWork W2109763600 @default.
• W3089661281 hasRelatedWork W2177518191 @default.
• W3089661281 hasRelatedWork W2196513091 @default.
• W3089661281 hasRelatedWork W2427873479 @default.
• W3089661281 hasRelatedWork W2554907366 @default.
• W3089661281 hasRelatedWork W3089661281 @default.
• W3089661281 hasRelatedWork W3112004363 @default.
• W3089661281 hasVolume "80" @default.
• W3089661281 isParatext "false" @default.
• W3089661281 isRetracted "false" @default.
• W3089661281 magId "3089661281" @default.
• W3089661281 workType "article" @default.